Abstract:538 Objectives: Prostate cancer is the most common cancer among men, and timely intervention may significantly facilitate treatment. The trophoblast cell surface antigen 2 (Trop2) is a transmembrane glycoprotein that regulates cell renewal and proliferation, and is found overexpressed in many cancers. Herein, we aim to evaluate the Trop2 expression level on different prostate cancer cell lines and apply radioimmunotherapy for the treatment of murine models of prostate cancer. Methods: The anti-Trop2 antibody (AF650, Research And Diagnostic Systems, Inc.) was conjugated with NOTA and DTPA for radiolabeling of Cu-64 (half-life 12.7 h) and Y-90 (half-life: 64.1 h), respectively. Radio-TLC was used to validate the radiolabeling and quantify the labeling efficiency. Relative Trop2 expression in LapC4, PC3, and 22RV1 prostate cancer cell lines was examined using flow cytometry. PET imaging and biodistribution studies in subcutaneous models of prostate cancer using 64Cu-NOTA-AF650 were performed to evaluate the tracer’s targeting capacity and specificity in vivo. Furthermore, 90Y-DTPA-AF650 was used for the treatment of the subcutaneous tumor model, with PBS and Y-90 labeled non-specific IgG as control groups. Tumor sizes and mouse body weight were examined every other day for two weeks. At the end time point, blood samples and tumor samples were collected and analyzed for toxicity evaluation. Results: Among the three prostate cancer cell lines, Trop2 expression was highest in LapC4 cells, while PC3 and 22RV1 displayed lower Trop2 expression. PET imaging revealed the tracer (64Cu-NOTA-AF650) uptake in LapC4 tumors to be about 12.2 ± 1.8 %ID/g, while values for PC3 and 22RV1 were 7.5 ± 1.9 %ID/g and 7.7 ± 0.6 %ID/g at 48 h post-injection, respectively. Treatment of LapC4 tumor-bearing mice with 90Y-DTPA-AF650 showed significant inhibition of tumor growth, compared with the treatment with PBS and non-specific IgG. During the study, mouse body weight did not decrease by more than 15% for all groups. Blood tests and tumor section staining suggested lower toxicity and better treatment effect of 90Y-DTPA-AF650 than 90Y-DTPA-IgG. Conclusion: This study showed the differentiated expression of Trop2 in 3 different prostate cancer cell lines, and 64Cu-NOTA-AF650 provided a specific tracer for imaging of prostate cancer with Trop2 overexpression. In addition, 90Y-DTPA-AF650 successfully curtailed tumor growth with lower off-target toxicity when compared with non-specific IgG. Overall, this targeted antibody holds great promise for PET imaging and immunoradiotherapy of prostate cancer.

On the shoulder of ADC: The development of 124I-IMMU-132, an iodine-124-labelled Trop-2-targeting molecular probe for micro-PET imaging

ImmunoPET imaging of Trop2 in patients with solid tumours

ImmunoPET Imaging of Trop2 Expression in Solid Tumors with Nanobody Tracers.

Theranostic Application of 64Cu/177lu-Labeled Anti-Trop2 Monoclonal Antibody in Pancreatic Cancer Tumor Models

ImmunoPET Imaging and Radioimmunotherapy of Prostate Cancer with an Anti-Trop2 Antibody

68Ga-My6349 PET/CT Imaging to Assess Trop2 Expression in Multiple Types of Cancer

ImmunoPET of trophoblast cell-surface antigen 2 (Trop-2) expression in pancreatic cancer

Novel Dual-Function Near-Infrared II Fluorescence and PET Probe for Tumor Delineation and Image-Guided Surgery.

Immuno-PET/CT Imaging of Trop2 with [18F]AlF-RESCA-T4 Differentiates Lung Cancer from Inflammation

Application Analysis of 124I-PPMN for Enhanced Retention in Tumors of Prostate Cancer Xenograft Mice.

Development and characterisation of [18F]TTDP, a novel T cell immunoglobulin and ITIM domain tracer, in humanised mice and non-human primates

Positron Emission Tomography Imaging of Programmed Death 1 Expression in Cancer Patients Using <SUP>124</SUP>I-Labeled Toripalimab A Pilot Clinical Translation Study

Positron Emission Tomography Imaging of Programmed Death 1 Expression in Cancer Patients Using 124I-Labeled Toripalimab

Trop2-Targeted Molecular Imaging in Solid Tumors: Current Advances and Future Outlook

An iodine‑labelled Antibody-drug conjugate PET probe for noninvasive monitoring of Nectin-4 expression in urothelial carcinoma

Sequential SPECT and NIR-II Imaging of Tumor and Sentinel Lymph Node Metastasis for Diagnosis and Image-Guided Surgery.

Preclinical and exploratory human studies of novel 68 Ga-labeled D-peptide antagonist for PET imaging of TIGIT expression in cancers

I-124 Radiolabeled Basiliximab for CD25-Targeted Immuno-PET Imaging of Activated T Cells

Pet Imaging of Tumor Metastasis Using 68Ga-Labeled A Novel Tumor-Homing Peptide Tmtp1

Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody

A novel ICG-labeled cyclic TMTP1 peptide dimer for sensitive tumor imaging and enhanced photothermal therapy in vivo